Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets

French pharma Pierre Fabre is offering up to $553 million in biobucks to work with Scorpion Therapeutics on developing and potentially commercializing two of the biotech’s preclinical lung cancer candidates.